Literature DB >> 25090283

The nasal approach to delivering treatment for brain diseases: an anatomic, physiologic, and delivery technology overview.

Per G Djupesland1, John C Messina, Ramy A Mahmoud.   

Abstract

The intricate pathophysiology of brain disorders, difficult access to the brain, and the complexity and high risks and costs of drug development represent major hurdles for improving therapies. Nose-to-brain drug transport offers an attractive alternative or addition to formulation-only strategies attempting to enhance drug penetration into the CNS. Although still a matter of controversy, many studies in animals claim direct nose-to-brain transport along the olfactory and trigeminal nerves, circumventing the traditional barriers to CNS entry. Some clinical trials in man also suggest nose-to-brain drug delivery, although definitive proof in man is lacking. This review focuses on new nasal delivery technologies designed to overcome inherent anatomical and physiological challenges and facilitate more efficient and targeted drug delivery for CNS disorders.

Entities:  

Mesh:

Year:  2014        PMID: 25090283     DOI: 10.4155/tde.14.41

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  61 in total

1.  Intranasal delivery of obidoxime to the brain prevents mortality and CNS damage from organophosphate poisoning.

Authors:  Jishnu K S Krishnan; Peethambaran Arun; Abhilash P Appu; Nivetha Vijayakumar; Taíza H Figueiredo; Maria F M Braga; Sudikshya Baskota; Cara H Olsen; Natalia Farkas; John Dagata; William H Frey; John R Moffett; Aryan M A Namboodiri
Journal:  Neurotoxicology       Date:  2016-01-02       Impact factor: 4.294

2.  Macrophage exosomes as natural nanocarriers for protein delivery to inflamed brain.

Authors:  Dongfen Yuan; Yuling Zhao; William A Banks; Kristin M Bullock; Matthew Haney; Elena Batrakova; Alexander V Kabanov
Journal:  Biomaterials       Date:  2017-07-10       Impact factor: 12.479

3.  Dabigatran ameliorates post-haemorrhagic hydrocephalus development after germinal matrix haemorrhage in neonatal rat pups.

Authors:  Damon Klebe; Jerry J Flores; Devin W McBride; Paul R Krafft; William B Rolland; Tim Lekic; John H Zhang
Journal:  J Cereb Blood Flow Metab       Date:  2016-12-20       Impact factor: 6.200

Review 4.  Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.

Authors:  Thomas C Chen; Clovis O Da Fonseca; Axel H Schönthal
Journal:  Am J Cancer Res       Date:  2015-04-15       Impact factor: 6.166

5.  Guanidinylated Neomycin Conjugation Enhances Intranasal Enzyme Replacement in the Brain.

Authors:  Wenyong Tong; Chrissa A Dwyer; Bryan E Thacker; Charles A Glass; Jillian R Brown; Kristina Hamill; Kelley W Moremen; Stéphane Sarrazin; Philip L S M Gordts; Lara E Dozier; Gentry N Patrick; Yitzhak Tor; Jeffrey D Esko
Journal:  Mol Ther       Date:  2017-08-12       Impact factor: 11.454

6.  Intranasally administered IGF-1 inhibits spreading depression in vivo.

Authors:  Yelena Y Grinberg; Lois A Zitzow; Richard P Kraig
Journal:  Brain Res       Date:  2017-09-23       Impact factor: 3.252

7.  Intranasal delivery of dexamethasone efficiently controls LPS-induced murine neuroinflammation.

Authors:  G Meneses; G Gevorkian; A Florentino; M A Bautista; A Espinosa; G Acero; G Díaz; A Fleury; I N Pérez Osorio; A Del Rey; G Fragoso; E Sciutto; H Besedovsky
Journal:  Clin Exp Immunol       Date:  2017-09-07       Impact factor: 4.330

8.  Intranasal delivery of N-terminal modified leptin-pluronic conjugate for treatment of obesity.

Authors:  Dongfen Yuan; Xiang Yi; Yuling Zhao; Chi-Duen Poon; Kristin M Bullock; Kim M Hansen; Therese S Salameh; Susan A Farr; William A Banks; Alexander V Kabanov
Journal:  J Control Release       Date:  2017-03-24       Impact factor: 9.776

9.  Visualization and Quantification of Nasal and Olfactory Deposition in a Sectional Adult Nasal Airway Cast.

Authors:  Jinxiang Xi; Jiayao Eddie Yuan; Yu Zhang; Dannielle Nevorski; Zhaoxuan Wang; Yue Zhou
Journal:  Pharm Res       Date:  2016-03-04       Impact factor: 4.200

10.  Intranasal Administration of TAT-Conjugated Lipid Nanocarriers Loading GDNF for Parkinson's Disease.

Authors:  Sara Hernando; Enara Herran; Joana Figueiro-Silva; José Luis Pedraz; Manoli Igartua; Eva Carro; Rosa Maria Hernandez
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.